Tanaka, Atsushi
Imai, Takumi
Toyoda, Shigeru
Sugimoto, Kazuhiro
Yoshida, Ruka
Furuta, Machi
Node, Koichi
,
Funding for this research was provided by:
Astellas Pharma
Article History
Received: 19 May 2023
Accepted: 1 July 2023
First Online: 7 July 2023
Declarations
:
: The Ethics Committee of Saga University Hospital approved the protocol of this sub-analysis. Written informed consent for participation in the PROTECT trial was obtained from all subjects.
: All authors have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language. If the manuscript is accepted, we approve it for publication in the Cardiovascular Diabetology.
: AT received honoraria from Boehringer Ingelheim Japan and research funding from GlaxoSmithKline, Takeda, Bristol-Myers Squibb and Novo Nordisk. TI received lecture fees from JCR Pharmaceuticals and KyowaKirin and outsourcing fees from Organization for Clinical Medicine Promotion. ST received honoraria from AstraZeneca and Bayer. KS received honoraria from Eli Lilly Japan. KN received honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim Japan, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe Pharma, MSD, Novartis Pharma, Novo Nordisk Pharma, Ono Pharmaceutical, Otsuka, and Takeda Pharmaceutical, research grant from Asahi Kasei, Astellas, Boehringer Ingelheim Japan, Fuji Yakuhin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Novartis Pharma, and Teijin Pharma, and scholarship from Bayer Yakuhin, Medtronic, and Teijin Pharma. All other authors declare no competing interests.